Why the study?
In vitro hERG channel patch-clamp assays are needed to predict compound-induced QT prolongation prior to first-in-human testing.
This protocol provides a standardized methodology for the in vitro hERG channel patch-clamp assay, a critical early screen for predicting compound-induced QT prolongation in drug development.
No takes yet. Share an insight, caveat, or question.
Novel in vitro hERG protocols may refine early QT screening; leaves open clinical predictive value.
Goineau et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: